Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Corporate Reputation of Pharma Companies, 2016: Perspective of 53 Respiratory Patient Groups (2017 Edition) - Research and Markets

Research and Markets
Posted on: 27 Oct 17

The "The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 53 Respiratory Patient Groups (2nd Edition)" report has been added to Research and Markets' offering.

These results are derived from a global review of pharma's corporate reputation (conducted November 2016 to early-February 2017).

This report is based on the opinions of 53 respiratory patient groups, from Finland (8), USA (5), Spain (4), and 19 other countries.

The specialty areas of the respiratory patient groups: asthma (8), cystic fibrosis (8), COPD (7), allergy (2), lung cancer (2), and respiratory conditions in general (26).

11 pharma companies are included in this 2016 respiratory analysis:

  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • GSK
  • Merck & Co
  • Novartis
  • Pfizer
  • Roche
  • Sandoz
  • Teva

7 indicators show the corporate reputation of individual pharma companies:

  • Patient centricity.
  • Information for patients.
  • Patient safety.
  • Usefulness of products.
  • Transparency.
  • Integrity.
  • Patient-group relationships (new for 2016).


  • 51.0% of 2016's 53 respondent respiratory patient groups thought that the pharma industry had an Excellent or Good corporate reputation (37.9% of patient groups worldwide thought the same).
  • However, only 15% of the respiratory patient groups thought that the pharma industry's corporate reputation had improved over the past five years (compared with 23% of respondents therapy wide). As many as 33% of respiratory patient groups thought that pharma's corporate reputation had declined (against 29% therapy wide).
  • Respiratory patient groups were, on the whole, positive about many of the pharma industry's activities in 2016. Some 77% stated that pharma was Excellent or Good at creating high-quality products (compared with 64% of patient groups therapy wide).
  • Nonetheless, respiratory patient groups sent pharma a clear message in 2016: the key task for improving corporate reputation (out of a list of 15 potential choices) is to do more to create high-quality, useful products (noted by 21% of the respiratory patient groups, but by only 11% of patient groups therapy wide).

For more information about this report visit

View source version on

Business Wire

Last updated on: 27/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.